menu
    • menu
    [{"orgOrder":0,"company":"GBI","sponsor":"Allterum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"4A10","moa":"IL-7R?","graph1":"Oncology","graph2":"Preclinical","graph3":"GBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBI \/ Allterum Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GBI \/ Allterum Therapeutics"},{"orgOrder":0,"company":"GBI","sponsor":"NanoRetinal","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"NAR-001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"GBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBI \/ NanoRetinal","highestDevelopmentStatusID":"4","companyTruncated":"GBI \/ NanoRetinal"}]

    Find Clinical Drug Pipeline Developments & Deals by GBI

    Menu

    GBI

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GBI

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            GBI

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAR-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : NanoRetinal

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GBI Partners with NanoRetinal to Advance Vision-Restoring Therapy for Retinal Diseases

                            Details : The partnership to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (IRD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 09, 2025

                            Lead Product(s) : NAR-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : NanoRetinal

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GBI

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            GBI

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 4A10

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Allterum Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GBI Biomanufacturing And Allterum Collaborate on Therapeutic Antibody Trials

                            Details : The collaboration aims to advance Allterum's lead candidate 4A10, a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers, into clinic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : 4A10

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Allterum Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth